Laddar...
Evaluation of Second-Line Anti-VEGF after First-Line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter “SLAVE” Study
Background: The optimal anti-angiogenic strategy as second-line treatment in RAS wild-type metastatic colorectal cancer (mCRC) treated with anti-EGFR (Epidermal Growth Factor Receptor) based first-line treatment is still debated. Methods: This multicenter, real-world, retrospective study is aimed at...
Sparad:
| I publikationen: | Cancers (Basel) |
|---|---|
| Huvudupphovsmän: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
MDPI
2020
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7281759/ https://ncbi.nlm.nih.gov/pubmed/32429380 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12051259 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|